Apeloa Pharmaceutical presented its multiple top-notch technology platforms and comprehensive CDMO services to global industry leaders at the 7th CMC-China Pharmaceutical Industry Expo in Suzhou this month.

Apeloa’s Chairman and CEO Brian Zhu, together with his CDMO team, highlighted Apeloa’s various platforms at the expo, including flow chemistry, peptides, synthetic biology and biocatalysis. The team spoke widely with visitors about exploring new partnerships and advancing pharmaceutical innovation around the world.

Zhu was invited to speak at the API Entrepreneurs Annual Conference, delivering a high value presentation titled, “Empowering global pharma innovation through Chinese pharmaceutical manufacturing.”

During his speech Zhu spoke extensively about the increasing prominence of China’s innovative drugs globally, underpinned by support from government policies for their development. He provided in-depth explanations into the evolution of China’s CDMO sector, analyzing core factors behind companies achieving critical breakthroughs. These factors, Zhu emphasized, have allowed China’s CDMOs to become key instigators of pharmaceutical innovation worldwide, by offering distinct advantages in cost control, operational efficiency and compliance management.

The CMC-China exhibition centered around the theme, “Breakthrough, Symbiosis, Globalization,” and brought together experts from all parts of the pharmaceutical value chain. Altogether, it drew over 20,000 attendees, including over 450 exhibitors and 600 speakers. As a flagship ecosystem platform in the pharmaceutical industry, CMC-China presented a valuable opportunity for companies to meet and engage with clients and partners from around the world.

The CMC-China conference also released the “2025 China Pharmaceutical Industry TOP101 and Top 10 Core Industry Chains” rankings, drawing on in-depth research and data accumulation by the Global Pharma Navigator team.

Apeloa received industry honors on the following four lists:

- 2025 China Pharmaceutical Industry TOP101

- 2025 China API Business TOP30

- 2025 China Small-Molecule CDMO TOP25

- 2025 China Synthetic Biomanufacturing TOP101

Such recognitions represent an endorsement of Apeloa’s contributions to the industry, underscoring its strength and commitment across multiple domains of pharmaceutical manufacturing. In the future, Apeloa seeks to further deepen its value and expertise in pharma manufacturing to promote continuous development of the industry.